On May 13, 2022 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported it has received approval from a second Human Research Ethics Committee (HREC) to conduct the Company’s Phase 2 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer (Press release, Amplia Therapeutics, MAY 13, 2022, View Source;[email protected] [SID1234614532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company recently announced (6 April 2022) that it received HREC approval to initiate the trial at sites in NSW, Australia. As noted in that announcement, the Company was awaiting the outcome of a second pending HREC application covering sites in Victoria, Australia. This second approval has now been received, allowing the Company to accelerate recruitment into the trial. No further HREC approvals are pending, and the Company now adjusts its focus to the trial’s execution phase.

Dr John Lambert, Amplia’s CEO and Managing Director noted that "This second HREC approval will allow us to recruit patients more rapidly and begin to generate early efficacy and safety results in people with pancreatic cancer. Our focus is now on timely recruitment and execution of a high-quality trial that will support our future development plans for AMP945 in this very dangerous disease."

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.